What type of study is this?

This is a Population-based analysis study.

September 10, 2025

FLOT vs. CROSS in adenocarcinoma of the esophagus and gastroesophageal junction: External validation of the ESOPEC-trial using a population-based matched-cohort study

Key Points

FLOT chemotherapy improves survival in patients with adenocarcinoma compared to CROSS.
Study confirms survival advantage based on real-world data from the German Cancer Registry.
Population-based analysis utilized matched cohorts for robust validation of trial findings.
Findings highlight the potential for FLOT as a preferred treatment strategy in clinical settings.

Abstract

Background: The ESOPEC trial recently demonstrated a survival advantage of perioperative FLOT chemotherapy over neoadjuvant CROSS chemoradiation in patients with resectable esophageal and gastroesophageal junction adenocarcinoma. To validate these findings in a real-world setting, we conducted a population-based analysis using by the German Cancer Registry Group of the Society of German Tumor Centers (Table 1).

FLOT vs. CROSS in adenocarcinoma of the esophagus and gastroesophageal junction: External validation of the ESOPEC-trial using a population-based matched-cohort study

Key Points

Abstract

Cite This Study

Also Consider

Also Consider